shutterstock_544602286_jon_bilous
Jon Bilous / Shutterstock.com
4 May 2023AmericasLiz Hockley

Vizgen accuses Harvard and 10x of patent licence cover-up

Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
5 May 2022   Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.
Biotechnology
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.

More on this story

Big Pharma
5 May 2022   Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.
Biotechnology
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.

More on this story

Big Pharma
5 May 2022   Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.
Biotechnology
8 June 2023   Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
13 July 2023   Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.